⚠️ Research Use Only. This post is educational and does not constitute medical advice. All peptides discussed are sold for research purposes only. See our full disclaimer.
Overview
Cerebrolysin is a porcine-derived peptide mixture studied extensively for neurological conditions including stroke, TBI, and dementia.
What is Cerebrolysin?
Cerebrolysin is unusual among peptides on this list — it's not a single peptide but a complex mixture of low-molecular-weight peptides and free amino acids derived from purified porcine brain proteins. It's been on the market for over 50 years in Europe, Russia, and parts of Asia, with one of the larger clinical research databases of any neurological compound.
The proposed mechanism is neurotrophic factor mimicry. The peptide fragments in Cerebrolysin appear to act like endogenous neurotrophic factors — BDNF, GDNF, and NGF — supporting neuron survival, axon growth, and synaptic plasticity. Unlike pure recombinant neurotrophic factors, Cerebrolysin's small peptide fragments cross the blood-brain barrier.
Clinical research has focused on stroke recovery, traumatic brain injury, and vascular dementia. Several meta-analyses of Cerebrolysin in acute ischemic stroke have shown modest but consistent improvements in neurological recovery scores, particularly when administered within the first days post-event. TBI research has shown similar moderate benefits in functional outcomes.
Cerebrolysin is administered intravenously or intramuscularly, with typical clinical protocols using 10-30 mL daily over 10-21 day cycles. It's a pharmaceutical product (manufactured by Ever Neuro Pharma), not a research powder, and the supply chain is meaningfully different from typical research peptides. It is not FDA approved and not legally available in the United States through normal channels.
Top Research Uses
- Stroke recovery research
- TBI research
- Dementia research
- Neurological function
- Neuroprotection
Mechanism of Action
Mixture of low-molecular-weight peptides and amino acids that mimic neurotrophic factor activity (BDNF, GDNF, NGF-like effects)
Research Parameters
| Half-Life | Variable across components |
| Typical Research Dose | Clinical protocols use 10-30 mL IV over 10-21 days |
| Administration Route | Intravenous, intramuscular |
| Reported Side Effects | Generally well-tolerated; possible agitation, headache, injection site reactions; pre-treatment fever or hypersensitivity rare |
Dosing ranges cited from published research literature. These are not recommendations for human use. Cerebrolysin is a research compound — not for human consumption.
Research Strength: High
Cerebrolysin has a substantial body of preclinical research supporting its studied applications. Multiple independent studies have examined its mechanisms and effects in animal models.
Vendor & Sourcing Notes
Pharmaceutical product available in Europe, Russia, China, and parts of Asia; not FDA approved
Always request third-party HPLC purity reports and mass spectrometry verification when sourcing research peptides. Quality varies significantly between suppliers.
Research Use Only — Compliance Notice
The information on this page is intended for educational and informational purposes only. Cerebrolysin (Cerebrolysin) is a research compound sold for laboratory research purposes only. It has not been approved by the FDA for human use. Nothing on this page constitutes medical advice or is intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Consult a qualified healthcare professional before considering any peptide-related protocols.
